Cyclerion Therapeutics (CYCN) EBITDA (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly EBITDA of -$1.0 million for Q3 2025, up 10.82% year-over-year from -$907814.4 in Q3 2024, and up 39.83% quarter-over-quarter from -$1.7 million in Q2 2025.
Cyclerion Therapeutics (CYCN) EBITDA (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' EBITDA history runs 8 years deep, the most recent figure standing at -$1.0 million for Q3 2025.
- In Q3 2025, EBITDA rose 10.82% year-over-year to -$1.0 million; the TTM figure through Sep 2025 stood at -$3.6 million (up 38.68% YoY), while the FY2024 annual figure was -$3.6 million, up 71.99% from the prior year.
- EBITDA for Q3 2025 stood at -$1.0 million, up from -$1.7 million in the prior quarter.
- The five-year high for EBITDA was $502000.0 in Q4 2024, with the low at -$16.2 million in Q2 2021.
- The 5-year median for EBITDA is -$3.3 million (2023), against an average of -$5.9 million.
- The sharpest annual moves came in 2023 and 2024: EBITDA slumped 33.13% in 2023, then surged 127.97% in 2024.
- Cyclerion Therapeutics' EBITDA stood at -$14.3 million in 2021, then soared by 68.93% to -$4.5 million in 2022, then soared by 59.71% to -$1.8 million in 2023, then soared by 127.97% to $502000.0 in 2024, then sank by 300.4% to -$1.0 million in 2025.
- Business Quant data shows CYCN's EBITDA at -$1.0 million in Q3 2025, -$1.7 million in Q2 2025, and -$1.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 133.12 Mn |
| 10 | Cyclerion Therapeutics | 12.29 Mn | 9.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | -1.67 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Dec 31, 2024 | 502,000.00 |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -1.38 Mn |
| Mar 31, 2024 | -1.62 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Sep 30, 2023 | -6.02 Mn |
| Jun 30, 2023 | -1.87 Mn |
| Mar 31, 2023 | -3.28 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -4.52 Mn |
| Jun 30, 2022 | -13.43 Mn |
| Mar 31, 2022 | -12.98 Mn |
| Dec 31, 2021 | -14.34 Mn |
| Sep 30, 2021 | -11.29 Mn |
| Jun 30, 2021 | -16.18 Mn |
| Mar 31, 2021 | -13.40 Mn |
| Dec 31, 2020 | -19.22 Mn |